Agios Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts. The company focuses on discovering and developing innovative therapies for rare, genetically defined metabolic diseases, particularly in the field of classical hematology. Its lead product, mitapivat (marketed as PYRUKYND and AQVESME), is an approved oral therapy for adults with pyruvate kinase (PK) deficiency and thalassemia.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
54,028
36,498
26,823
14,240
Cost of Sales
6,345
4,165
2,881
1,704
Gross Profit
47,683
32,333
23,942
12,536
Selling, General & Administrative Expenses
180,280
156,784
119,903
121,673
Research & Development Expenses
339,535
301,286
295,526
279,910
Operating Profit
(472,132)
(425,737)
(391,487)
(389,047)
Interest and Investment Income
56,379
48,083
33,344
12,793
Non-Operating Income
1,956
1,095,623
6,055
144,453
Total Non-Operating Income
58,335
1,143,706
39,399
157,246
Income Before Provision for Income Taxes
(413,797)
717,969
(352,088)
(231,801)
Provision for Income Taxes
(1,016)
44,244
—
—
Consolidated Net Income
(412,781)
673,725
(352,088)
(231,801)
Net Income Attributable to Common Shareholders
(412,781)
673,725
(352,088)
(231,801)
Basic EPS
-7.12
11.86
-6.33
-4.23
Diluted EPS
-7.12
11.64
-6.33
-4.23
Basic Weighted Average Shares Outstanding
57,972
56,807
55,651
54,789
Diluted Weighted Average Shares Outstanding
57,972
57,889
55,651
54,789
Shares Outstanding
58,449
57,156
55,945
55,040
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
89,130
76,247
88,205
139,259
Short-Term Investments
765,295
817,463
688,723
643,860
Total Cash and Cash Equivalents
854,425
893,710
776,928
783,119
Accounts Receivable
10,577
4,109
2,810
2,206
Total Trade Receivables
10,577
4,109
2,810
2,206
Inventories
32,920
27,616
19,076
8,492
Other Current Assets
44,130
40,165
35,021
38,955
Total Current Assets
942,052
965,600
833,835
832,772
Net Property, Plant & Equipment
41,229
54,554
69,791
88,116
Long-Term Investments
310,013
638,321
29,435
313,874
Other Long-Term Assets
3,931
4,724
4,057
3,956
Total Assets
1,297,225
1,663,199
937,118
1,238,718
Accounts Payable
18,355
16,643
9,780
18,616
Accrued Expenses
45,459
46,861
43,167
30,350
Current Portion of Leases
18,392
16,781
15,008
13,663
Other Current Liabilities
—
871
—
—
Total Current Liabilities
82,206
81,156
67,955
62,629
Leases
21,815
40,207
56,988
71,996
Other Long-Term Liabilities
90
880
1,156
3,279
Total Long-Term Liabilities
21,905
41,087
58,144
75,275
Total Liabilities
104,111
122,243
126,099
137,904
Common Stock
75
73
72
0
Treasury Stock
(802,486)
(802,486)
(802,486)
(802,486)
Additional Paid-in Capital
2,555,037
2,493,811
2,436,523
2,386,325
Accumulated Other Comprehensive Income
2,193
(1,518)
(441)
(12,535)
Retained Earnings
(561,705)
(148,924)
(822,649)
(470,561)
Total Common Shareholders' Equity
1,193,114
1,540,956
811,019
1,100,743
Total Shareholders' Equity
1,193,114
1,540,956
811,019
1,100,743
Total Liabilities and Shareholders' Equity
1,297,225
1,663,199
937,118
1,238,718
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(412,781)
673,725
(352,088)
(231,801)
Depreciation & Amortization
5,177
5,653
6,623
8,564
Share-Based Compensation Expense
52,552
42,847
44,766
49,296
Other Adjustments
15,117
(1,092,298)
23,694
(119,104)
Changes in Trade Receivables
(6,468)
(1,299)
(604)
(1,759)
Changes in Inventories
(5,304)
(8,540)
(10,584)
(8,492)
Changes in Accounts Payable
1,746
6,601
(8,733)
3,436
Changes in Accrued Expenses
(1,402)
3,694
12,817
(1,617)
Changes in Income Taxes Payable
(871)
871
—
—
Changes in Other Operating Activities
(20,743)
(21,095)
(11,953)
(8,001)
Cash from Operating Activities
(372,977)
(389,841)
(296,062)
(309,478)
Capital Expenditure
(4,316)
(1,685)
(999)
(4,881)
Proceeds from Sale of Property, Plant & Equipment
—
40
1,325
964
Purchases of Investments
(641,759)
(1,542,433)
(417,930)
(1,030,781)
Proceeds from Sale of Investments
1,033,259
818,383
674,679
1,146,175
Other Investing Activities
(10,000)
1,089,136
(17,500)
131,784
Cash from Investing Activities
377,184
363,441
239,575
243,261
Issuance of Common Shares
8,676
14,442
5,433
2,681
Net Issuance / (Repurchases) of Common Shares
8,676
14,442
5,433
2,681
Other Financing Activities
—
—
—
(331)
Cash from Financing Activities
8,676
14,442
5,433
2,350
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash